Weak Drug Sales Undermine BIIB's Earnings Beat

The stock looks to have hit a plateau in mid-January

Digital Content Manager
Apr 22, 2021 at 9:57 AM
facebook X logo linkedin


The shares of Biogen Inc (NASDAQ:BIIB) were last seen down 3.9% at $259.23, even after the pharmaceutical concern posted first-quarter earnings of $5.34 per share, which topped analysts' estimates. The firm lifted its 2021 adjusted profit forecast, adding that it expects its experimental  Alzheimer's drug, aducanumad, to win approval in the U.S. by June, and bring in sales later this year. Biogen's revenue also beat expectations, though weak sales for multiple sclerosis drug Tecfidera could be weighing on the shares this morning. 

The equity has been middling since it managed to reclaim the $260 level in mid-January. And though BIIB briefly broke out atop its 320-day moving average, the trendline has acted as a ceiling on the charts, continuing to loom overhead during today's trading. Year-to-date, BIIB sports a 5.8% lead. 

Option traders were bearish ahead of Biogen's earnings event. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), BIIB sports a 10-day put/call volume ratio of 1.67, which stands in the 93rd percentile of its annual range. This means puts are outnumbering calls at a quicker-than-usual clip. 

Short-term option traders have been incredibly put-biased, too. The security's Schaeffer's put/call open interest ratio (SOIR) of 1.66 stands in the top-most percentile of all readings from the past 12 months. 

The brokerage bunch has also taken a hesitant stance. Of the 24 in coverage, 17 consider BIIB a "hold" or worse rating, while the remaining seven say "buy" or better. The 12-month consensus price target of $290.24, meanwhile, is a 12.3% premium to current levels. 

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI